Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
University of Florida
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Princess Maxima Center for Pediatric Oncology
St. Jude Children's Research Hospital
University of Alberta
St. Jude Children's Research Hospital
Sun Yat-sen University
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Children's National Research Institute
Mayo Clinic
Milton S. Hershey Medical Center
Massachusetts General Hospital
Children's Hospital of Philadelphia
Emory University
Boston Children's Hospital
Children's Hospital of Philadelphia
Beijing Children's Hospital
Institut Claudius Regaud
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
New Approaches to Neuroblastoma Therapy Consortium
St. Jude Children's Research Hospital
Masonic Cancer Center, University of Minnesota
University of Wisconsin, Madison
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Nanjing First Hospital, Nanjing Medical University
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
University Hospital, Clermont-Ferrand
Nationwide Children's Hospital
First Affiliated Hospital of Zhejiang University
Sichuan University
Nanjing First Hospital, Nanjing Medical University
Dana-Farber Cancer Institute
Princess Maxima Center for Pediatric Oncology
Sun Yat-sen University
Nationwide Children's Hospital